AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) stock performance was -8.38% in last session and finished the day at $11.92. Traded volume was 1.46million shares in the last session and the average volume of the stock remained 612.44K shares. The beta of the stock remained 1.69. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) insider ownership is 0.10%.

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Director Kenneth B. Lee, Jr. sold 12,665 shares of the stock in a transaction that occurred on Thursday, March 6th. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) dropped -6.90 percent to $11.46 Friday on volume of 1.21million shares. The intra-day range of the stock was $11.17 to $12.34. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has a market capitalization of $677.19million.

Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it plans to release fourth quarter 2013 financial and operating results after market close on Thursday, March 6, 2014. Ken Reali, President and Chief Executive Officer of Baxano Surgical Inc. (Nasdaq:BAXS), and Tim Shannon, Interim Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. Baxano Surgical Inc (NASDAQ:BAXS)’s stock on Mar 7, 2014 reported a decrease of -11.41% to the closing price of $1.49. Its fifty two weeks range is $0.92-$2.50. The total market capitalization recorded $67.34million. The overall volume in the last trading session was 1.08million shares. In its share capital, BAXS has 45.20million outstanding shares.

Flamel Technologies, S.A. (NASDAQ: FLML) today announced that it is offering to sell American Depositary Shares (ADSs), representing its ordinary shares, in an underwritten public offering. On Friday, shares of Flamel Technologies S.A. (ADR) (NASDAQ:FLML) dropped -5.70% to close the day at $10.10. Company return on investment (ROI) is -5.00% and its monthly performance is recorded as -3.53%. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) quarterly revenue growth is 34.67%.